论文部分内容阅读
瑞替加滨(retigabine,1),化学名为[2-氨基-4-[[(4-氟苯基)甲基]氨基]苯基]氨基甲酸乙酯,是英国葛兰素史克和加拿大Valeant公司共同研发的一种新型神经元钾通道开放剂[1]。该药可作用于神经元的电压门控钾离子通道(KCNQ),调节M型钾电流,促使钾离子外流,使静息膜电位超极化,抑制动作电位的产生,从而降低神经细胞的兴奋性,呈现抗癫痫效应[2]。1已于2011年3和6月分别
Retigabine (1) has the chemical name [2-amino-4 - [[(4-fluorophenyl) methyl] amino] phenyl] carbamate, which is the UK’s GlaxoSmithKline and Canada Valeant company jointly developed a new neuronal potassium channel opener [1]. The drug can act on neuronal voltage-gated potassium channels (KCNQ), regulate the type M potassium current, promote potassium efflux, the resting membrane potential hyperpolarization, inhibition of action potential, thus reducing the excitement of nerve cells Sexual, showing antiepileptic effect [2]. 1 was completed in March and June 2011 respectively